Could the Nsp1 protein be a novel drug target for COVID-19?
A study of the SARS-CoV-2 nonstructural protein 1 (Nsp1) showed it can supress translation and inhibit anti-viral defence mechanisms, making it a potential target for drugs.
List view / Grid view
A study of the SARS-CoV-2 nonstructural protein 1 (Nsp1) showed it can supress translation and inhibit anti-viral defence mechanisms, making it a potential target for drugs.
Scientists found in a murine model of acute respiratory distress syndrome (ARDS) that cannabidiol (CBD) helped the lungs recover from excessive inflammation caused by COVID-19.
The newly identified hallmarks of critical COVID-19 indicate a combination of interferon supplementation and anti-inflammatory therapies could be effective in treating patients with severe COVID-19 symptoms.
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
Scientists demonstrated that remdesivir can inhibit SARS-CoV-2 replication in human lung cells and improve lung function in mice with COVID-19.
This article outlines the ideal scientific research that should be conducted to design a prophylactic to combat COVID-19.
Researchers report COVID-19 can cause a range of severe neurological symptoms, which may be the main presentation of COVID-19 in some patients.
The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
Researchers experimenting on macaques reveal they were protected against reinfection up to a month after the initial exposure to SARS-CoV-2.
Scientists reveal eight new molecules, five of which are already US FDA-approved, that can block the polymerase reaction SARS-CoV-2 uses to replicate its genome.
Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
Dr Ulrich Kutschera outlines why more studies are necessary before the spread and deadliness of the novel coronavirus is fully understood.
A team of researchers has analysed how SARS-CoV-2 hijacks the proteins in its host cells to aid replication and infect nearby cells.
Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
A study of blood samples from COVID-19 patients has allowed a team to reveal six molecular targets that could be used to develop treatments for the virus.